Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Agreement expands Mycovia’s worldwide commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States

Mycovia continues to quickly develop VT-1161 as a possible first FDA-approved remedy for recurrent candidiasis that is vulvovaginal

DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a license that is exclusive development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, an dental antifungal item prospect, happens to be in period 3 clinical studies when it comes to remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million females worldwide every year.Continue reading